TY  - JOUR
T1  - Evre III-B meme kanserli hastalarda CEA ve CA 15-3 düzeylerinin takipteki önemi
TT  - The importance of monitoring of CEA and CA 15-3 levels in patients with stageIII-B breastcancer
AU  - Öztürk, Doğan
AU  - Oral, Süleyman
PY  - 2023
DA  - December
DO  - 10.18663/tjcl.1369602
JF  - Turkish Journal of Clinics and Laboratory
JO  - TJCL
PB  - DNT Ortadoğu Yayıncılık A.Ş.
WT  - DergiPark
SN  - 2149-8296
SP  - 696
EP  - 702
VL  - 14
IS  - 4
LA  - tr
AB  - Amaç: Meme kanserinin ilk tanıda%10-15'i lokal ileri meme kanseridir. Meme kanserinde tümör belirleyicileri grubunda karsinoembriyonik antijen (CEA) ve kanser antijeni 15-3 (CA 15-3) büyük önem taşır. Biz bu çalışmada evre IIIB meme kanserlerinde tümör belirleyicilerinin hastaların takibinde lokal nüks ve uzak organ metastaz ile ilişkisini ortaya koymaya çalıştık. Gereç ve Yöntemler: Ankara Onkoloji Hastanesi'ne 4 yıllık süre içerisinde başvuran evre IIIB meme kanseri olup neoadjuvan kemoterapi sonrası operabl olan 140 hasta retrospektif olarak incelendi. Bulgular: Çalışmaya 140 hasta dahil edildi. Başvuru anında; 54'ünde (%38,5) CEA düzeyi normal sınırlarda iken, CA 15-3 düzeyi 72'sinde (%51,4) normal sınırlarda idi. Kemoterapi sonrası ve bu hastaların 60’ında (%69,7) CEA düzeyleri normal, 46'sında (%67,6) CA 15-3 düzeyi normal sınırlarda idi. Kemoterapi sonrası CEA düzeyindeki düşüş oranı ile CA 15-3 düzeyindeki düşüş oranı p'ye göre
KW  - Meme kanseri
KW  - ileri evre
KW  - CEA
KW  - CA 15-3
KW  - lokal nüks
KW  - uzak metastaz
N2  - Aim: 10-15% of breast cancer is locally advancedbreastcancer at the time of initial diagnosis. Intergroup of tumor markers in breast cancer, carcinoembryonic antigen (CEA) andcancerantigen 15-3 (CA 15-3) are of great importance. Inthisstudy,we tried to reveal the relationshipbetweentumormarkers in stage IIIB breastcancerwithlocalrecurrenceanddistant organ metastasis in the follow-up of patients.Material and Methods: 140 patientswithstage IIIB breastcancerwhowereadmitted to Ankara OncologyHospitalwithin4yearsandwereoperableafterneoadjuvantchemotherapywhere retrospectively analyzed.Results: 140 patientswereincluded in thestudy. At the time of application, CEA levelwaswithinthe normal range in 54 (38.5%), the CA 15-3 levelwaswithinthe normal range in 72 (51.4%). Afterchemotherapyand in 60 (69.7%) of thesepatients, the CEA levelswere normal. In 46 (67.6%) of them, CA 15-3 levelwaswithin normal limits. The rate of decrease in CEA levelandthe rate of decrease in CA 15-3 levelafterchemotherapywas
CR  - Ahmed M. Kabel, Tumor markers of breast cancer: new prospectives, J. Oncol. Sci.2017; 3 (1) 5–11.
CR  - Ahmed M. Kabel, Fahad H. Baali, Breast cancer: insights into risk factors, pathogenesis, diagnosis and management, J. Cancer Res. Treat.2015; 3 (2) 28–33.
CR  - S.G. Wu, Z.Y. He, J. Zhou, et al, Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer, Breast.2014; 23 (1) 88–93.
CR  - J.X. Hing, C.W. Mok, P.T. Tan, et al., Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance, Breast .2020;(52) 95–101.
CR  - C. Van Poznak, M.R. Somerfield, R.C. Bast, et al., Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: american society of clinical oncology clinical practice guideline, J. Clin. Oncol.2015; 33 (24) 2695–2704.
CR  - B, Liang MM, Ye XB, Zhao WY. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol. 2015; Jan;3 (1):232-236.
CR  - B. Geng, M.M. Liang, X.B. Ye, W.Y. Zhao, Association of CA 15-3 and CEA with clinicopathological  parameters in patients with metastatic breast cancer, Mol. Clin. Oncol.2015; 3 (1) 232–236 .
CR  - X. Li, D. Dai, B. Chen, H. Tang, X. Xie, W. Wei, Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: a meta-analysis including.2018; 12,993.
CR  - R. Molina, J.M. Auge, B. Farrus, et al, Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer, Clin. Chem.2010; 56 (7) 1148–1157.
CR  - J.S. Lee, S. Park, J.M. Park, J.H. Cho, S.I. Kim, B.W. Park, Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers, Breast Cancer Res. Treat.2013; 141 (3) 477–484.
CR  - X. Li, D. Dai, B. Chen, H. Tang, X. Xie, W. Wei, Determination of the prognostic value of preoperative CA15-3 and CEA in predicting the prognosis of young patients with breast cancer, Oncol. Lett.2018; 16 (4) 4679–4688.
CR  - Y. Shao, X. Sun, Y. He, C. Liu, H. Liu, Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancerPLoS ONE. 2015;10 (7).
CR  - Jager W, Eibner K. Loner B ,et al. Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients. Anti-cancerRes.2000; 20(6D):5179-82.
CR  - Canizares F. Sola J, Perez M,Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer:a multivariate analysis.TumorBiol. 2001;22:273-81.
CR  - Lumachi F, Brands AA, ErmaniM. et al. Sensitivity of serum tumor markers CEA and CA 15-3 in Breast cancer recurrence  sandcor relation with different prognostic factors.  Anti-cancerRes .2000;2014751-5.
CR  - Soletormos G, HyltoftPetersen P, Progression criteria for cancer antigen 15.3 and carcinoembriyonic antigen in rnetastatic breast cancer compared by computer simulation of marker data-ClinChem.2000; 46:939-49.
CR  - Cheung KL, Graves CR, Robertson JE. Tumor marker measurements  in the diagnosis and  monitoring of breastcancer. CancerTreatRev.2000; 26:91-102.
CR  - J.X. Hing a c, C.W. Mok a c, P.T. Tan b, S.S. Sudhakar a, C.M. Seah a, W.P. Lee a c, S.M. Tan a Clinical utility of tumor marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance The Breast Volume 52, August 2020;Pages 95-101.
CR  - Dr. Diya Hasan Diagnostic impact of CEA and CA 15-3 on chemotherapy  monitoring of breast cancer patients J Circ Biomark. 2022 Jan-Dec; 11: 57–63.
CR  - S.Y. Bae 1, W. Lim 2, J. Jeong 3 et al ,8276P –The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients Annals of Oncology Volume 30, Supplement 5, October 2019, Page v93.
CR  - M.J. Duffy, S. Shering, F. Sherry, E. McDermott, N O’Higgins, CA 15–3: a Prognostic Marker in Breast Cancer, Int. J. Biol. Markers.2000 ;15 (4) 330–333.
UR  - https://doi.org/10.18663/tjcl.1369602
L1  - https://dergipark.org.tr/tr/download/article-file/3447361
ER  -